New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 14, 2014
09:18 EDTSNE, MM, BMY, ISIS, RUBI, GSK, PTX, TTWO, CSIQ, FOSL, SODA, PLUG, CLDX, P, ENZYOn The Fly: Pre-market Movers
HIGHER: Pernix Therapeutics (PTX), up 42% after acquiring TREXIMET tablets for migraine from GlaxoSmithKline (GSK)... Isis Pharmaceuticals (ISIS), up 9.6% after Phase 2 results for ISIS-GCGR for diabetes reported... Canadian Solar (CSIQ), up 1.7% after partnering with Ikea to build 3.6MW solar systems... Pandora (P), up 1.4% following upgrade at Raymond James... Rubicon Project (RUBI), up 22% after upgraded at Oppenheimer and RBC Capital following its Q1 earnings report... Celldex (CLDX), up 10.5% after announcing collaboration agreement with Bristol-Myers (BMY)... Millennial Media (MM), up 3.4% after CEO Barrett purchases 291K shares. LOWER: Sony (SNE), down 5.6% after reporting FY13 results, guiding to losses in FY14... DOWN AFTER EARNINGS: Fossil (FOSL), down 6.5%... Enzymotec (ENZY), down 8.6%... Plug Power (PLUG), down 6.6%... SodaStream (SODA), down 3.2%... Take-Two (TTWO), down 3.5%.
News For SNE;P;CLDX;PLUG;SODA;FOSL;CSIQ;TTWO;PTX;GSK;RUBI;ISIS;BMY;MM;ENZY From The Last 14 Days
Check below for free stories on SNE;P;CLDX;PLUG;SODA;FOSL;CSIQ;TTWO;PTX;GSK;RUBI;ISIS;BMY;MM;ENZY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
August 22, 2014
12:39 EDTISIS, BMYThese five companies will benefit from increased ALS awareness, MarketWatch says
A recent surge in funding for Lou Gehrig's disease, or ALS, caused by the Ice Bucket challenge that is widespread on social media outlets, will benefit five pharmaceutical companies that are involved in the development of a cure for ALS, according to MarketWatch. The companies that are or have been involved in developing a treatment for ALS include Biogen Idec (BIIB), Avanir Pharmaceuticals (AVNR), Isis Pharmaceuticals (ISIS), Sanofi (SNY), and Bristol-Myers Squibb (BMY), MarketWatch added. Reference Link
11:59 EDTTTWO, SNEGameStop surges after Q2 EPS, revenue beat expectations
Subscribe for More Information
06:34 EDTCSIQChina not meeting shale gas goals, NY Times says
Subscribe for More Information
August 21, 2014
13:32 EDTBMYBristol-Myers, Pfizer announce approval of Eliquis for treatment of DVT, PE
Subscribe for More Information
August 20, 2014
15:35 EDTGSKGlaxoSmithKline receives FDA approval for Arnuity Ellipta in the U.S.
Subscribe for More Information
11:44 EDTGSKMylan completes second bidding round for GSK prescription portfolio, WSJ says
Mylan (MYL), TPG Capital, Advent International, KKR (KKR), Warburg Pincus and a few Indian prescription manufacturers have completed the second round of bidding for GlaxoSmith Kline's (GSK) portfolio of mature medications, according to The Wall Street Journal, citing people familiar with the sales process. GSK noted that it aims to sell a portfolio of drug brands in the U.S. and EU with yearly sales of approximately $1.66B. Reference Link
11:42 EDTPLUGOptions with decreasing implied volatility
Subscribe for More Information
08:30 EDTPTX, GSKPernix closes acquisition of Treximet
Subscribe for More Information
08:29 EDTGSK, PTXPernix Therapeutics to host conference call
Conference call to discuss acquisition of Treximet will be held on August 20 at 9 am. Webcast Link
08:27 EDTCSIQCanadian Solar completes sale of Good Light Solar Power Plant to BluEarth
Canadian Solar's wholly-owned subsidiary, Canadian Solar Solutions, has completed the sale of Good Light, a 10 MW AC solar power plant located in the town of Kawartha Lakes, Ontario, Canada, valued at over $60.3M, to a BluEarth Renewables subsidiary. This is the second of four planned solar projects being acquired by BluEarth from Canadian Solar, totalling 38.5 MW AC.
08:24 EDTPTXPernix Therapeutics management to meet with Needham
Subscribe for More Information
08:08 EDTPTXPernix sees FY15 revenue approximately $230M, consensus $214.07M
Sees FY15 adjusted EBITDA $95M.
08:07 EDTPTXPernix Therapeutics sees FY14 revenue $110M-$120M, consensus $116.87M
Subscribe for More Information
08:04 EDTGSK, PTXPOZEN announces U.S. rights for Treximet acquired by Pernix Therapeutics
Subscribe for More Information
08:03 EDTBMYBristol-Myers Pfizer to present new Eliquis data
Subscribe for More Information
08:02 EDTBMYBristol-Myers, Celgene enter collaboration agreement for OPDIVO, ABRAXANE
Subscribe for More Information
August 19, 2014
10:42 EDTPLUGOptions with decreasing implied volatility
Subscribe for More Information
09:51 EDTPPandora calls activate on renewed speculation of an activist investor
Pandora August weekly 27.5 and 29 calls are active on total call volume of 5K contracts (1K puts) on renewed speculation of an activist investor. August weekly call option implied volatility is at 77, September is at 58 and December is at 55; compared to its 26-week average of 55 according to Track Data. Active call volume suggests traders taking positions for upside price movement.
09:44 EDTPRumor: Pandora moves up on renewed speculation of an activist investor
Subscribe for More Information
09:20 EDTCSIQReported settlement offer positive for Chinese solar stocks, says Roth Capital
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use